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Abstract
Background: BRCA1 and BRCA2 mutations explain approximately one-fifth of the inherited susceptibility in
high-risk Finnish hereditary breast and ovarian cancer (HBOC) families. EMSY is located in the breast cancer-
associated chromosomal region 11q13. The EMSY gene encodes a BRCA2-interacting protein that has been
implicated in DNA damage repair and genomic instability. We analysed the role of germline EMSY variation in
breast/ovarian cancer predisposition. The present study describes the first EMSY screening in patients with
high familial risk for this disease.
Methods: Index individuals from 71 high-risk, BRCA1/2-negative HBOC families were screened for germline
EMSY sequence alterations in protein coding regions and exon-intron boundaries using Sanger sequencing
and TaqMan assays. The identified variants were further screened in 36 Finnish HBOC patients and 904
controls. Moreover, one novel intronic deletion was screened in a cohort of 404 breast cancer patients
unselected for family history. Haplotype block structure and the association of haplotypes with breast/ovarian
cancer were analysed using Haploview. The functionality of the identified variants was predicted using
Haploreg, RegulomeDB, Human Splicing Finder, and Pathogenic-or-Not-Pipeline 2.
Results: Altogether, 12 germline EMSY variants were observed. Two alterations were located in the coding region, five
alterations were intronic, and five alterations were located in the 3'untranslated region (UTR). Variant frequencies did not
significantly differ between cases and controls. The novel variant, c.2709 + 122delT, was detected in 1 out of 107 (0.9%)
breast cancer patients, and the carrier showed a bilateral form of the disease. The deletion was absent in 897 controls
(OR = 25.28; P = 0.1) and in 404 breast cancer patients unselected for family history. No haplotype was identified to
increase the risk of breast/ovarian cancer. Functional analyses suggested that variants, particularly in the 3'UTR, were
located within regulatory elements. The novel deletion was predicted to affect splicing regulatory elements.
Conclusions: These results suggest that the identified EMSY variants are likely neutral at the population level. However,
these variants may contribute to breast/ovarian cancer risk in single families. Additional analyses are warranted for rare
novel intronic deletions and the 3'UTR variants predicted to have functional roles.
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Background
Breast cancer (BC) is the most common cancer among
women in Western countries. In Finland, 4694 new BC
cases were diagnosed in 2012 (Finnish Cancer Registry).
Ovarian cancer (OC) is the most lethal gynaecologic ma-
lignancy in developed countries [1]. In 2012, 466 new
OC cases were diagnosed, making OC the tenth most
common cancer among Finnish women (Finnish Cancer
Registry). The genetic predisposition to both of these
diseases has been well recognized. Approximately 5–
10% of all of breast and ovarian cancer cases reflect
inherited genetic defects primarily in two well-known
high-penetrance breast and ovarian cancer genes,
BRCA1 (breast cancer 1, early onset) and BRCA2 (breast
cancer 2, early onset) [2–4]. Both of these genes encode
large proteins that play critical roles in the DNA repair
pathway (reviewed in [5]). Mutations in BRCA1 and
BRCA2 predispose to hereditary breast and ovarian can-
cer (HBOC) syndrome characterized by multiple family
members affected with breast or ovarian cancer or both,
early onset of BC, bilateral form of cancer, and the ap-
pearance of other cancers in family members, including
prostate, pancreatic and male BC [6]. Among Finnish
HBOC families, BRCA1/2 mutations are explain ap-
proximately 20% [7, 8]. Additionally, a low proportion of
additional HBOC predisposition in the Finnish families
reflects defects in other DNA repair pathway genes,
including CHEK2 (Checkpoint kinase 2), PALB2 (Partner
and localizer of BRCA2), RAD51C (RAD51 (S. cerevisiae)
Homologue C), and Abraxas [9–12]. Nevertheless,
additional HBOC predisposing genetic factors remains
unknown, and one potential approach is to screen the
candidate genes of proteins that interact with either
BRCA1 or BRCA2 in the DNA repair pathway.
One of the interacting proteins of BRCA2 is EMSY
(C11orf30) [13]. EMSY is located at chromosomal region
11q13 (11q13.5), which is associated with BC, particu-
larly the hormone receptor-positive form of the disease
[14]. EMSY encodes a protein with an evolutionary con-
served EMSY N-terminal domain that is unique in the
human genome [13]. The EMSY N-terminal domain has
a structure similar to the DNA-binding motif found in
transcription factors [15].
EMSY has been implicated in DNA repair and tran-
scriptional regulation. The interaction with BRCA2 corre-
lates EMSY to DNA repair with the observation that
EMSY localizes at DNA damage sites [13]. In addition, the
over-expression of a truncated form of EMSY results in a
chromosome instability phenotype in human mammary
epithelial cells, similar to that of cells showing a loss of
BRCA2 function [16]. The binding of EMSY to the
BRCA2 exon 3-encoding transcriptional activation do-
main represses the function of this domain [13]. In
addition, EMSY interacts with the chromatin remodelling
proteins Heterochromatin protein 1 β (HP1 β) and
BS69 [13]. EMSY has been implicated in the regula-
tion of nuclear receptor-mediated transcription [17],
the transcription of interferon-stimulated genes with
BRCA2 [18], and the transcription of antimetastatic
microRNA miR-31 [19].
EMSY is amplified in breast tumours [13, 20–23], and
this amplification is associated with the poor outcome of
BC [13, 20–22]. EMSY copy number changes have also
been observed in male breast tumours, but the copy
number gains are comparatively more frequent in female
breast tumours [24]. In addition to breast cancer, EMSY is
overexpressed in high-grade ovarian cancer [13, 25, 26]
and pancreatic cancer [27]. Previously, we examined the
association of EMSY single-nucleotide polymorphisms
(SNPs) in relation to prostate cancer predisposition and
identified a rare intronic SNP that increases the risk of
aggressive prostate cancer [28].
In the present study, we identified germline sequence
alterations in the EMSY gene, encoding a BRCA2-
interacting protein partner, which could contribute to
HBOC susceptibility by disrupting critical functions in
the DNA repair pathway. Thus, we sequenced the EMSY
coding region and exon-intron boundaries in a cohort of
71 Finnish BRCA1/2-negative HBOC patients pre-
screened for mutations in seven known breast cancer
genes and copy-number alterations at the genome-wide
scale [29, 30] and further analysed the identified variants
in additional HBOC patients and healthy controls. To
our knowledge, the present study is the first to analyse
germline EMSY alterations in susceptibility to HBOC in
high-risk families.
Methods
Patients and controls
Germline EMSY sequence alterations were screened in
index patients from 71 high-risk Finnish HBOC families.
Study material was collected from the Tampere University
Hospital Genetics Outpatient Clinic between January 1997
and May 2008. Patients belonging to a cohort of 82 high-
risk HBOC individuals previously well characterized and
screened for germline alterations in BRCA1, BRCA2,
CHEK2, PALB2, BRIP1, RAD50, and CDH1 genes and
germline copy number alterations at the genome-wide
scale [29, 30]. From the previously described cohort, we
included only the 71 affected index individuals in the
present study, including 57 females with BC, 8 females
with bilateral BC, 1 female with OC, and 5 females with
both BC and OC. Originally, all patients were determined
as negative for 28 Finnish BRCA1/2 founder-mutations
based on minisequencing and protein truncation tests
(PTTs) for BRCA1 exon 11 and BRCA2 exons 10 and 11.
Additionally, the exons and exon-intron boundaries of
BRCA1 and BRCA2 have previously been analysed using
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Sanger sequencing and Multiplex Ligation-dependent
Probe amplification (MLPA) to exclude other mutations
[29]. All of the identified EMSY sequence alterations were
screened from the DNA samples of 36 additional index
patients from HBOC families collected from the
Turku region and from anonymous healthy female
blood donors (n = 380–904) (referred as controls) ob-
tained from the Finnish Red Cross. Additionally, a
rare novel c.2709 + 122delT variant was further
screened in a cohort of 404 BC cases unselected for
family history from the Tampere region [31]. All pa-
tients were informed of the analyses and provided
written consent to the use of existing DNA samples
in the present study. The Ethical Committees of
Tampere and Turku University Hospitals and the
National Authority for Medicolegal Affairs approved
this research project.
Sample preparation and mutation screening
Genomic DNA from control samples was extracted from
peripheral leukocytes using the Puregene Kit according
to the manufacturer’s instructions (Gentra Systems,
Inc., Minneapolis, MN, USA). Mutation screening was
achieved through Sanger sequencing. Reference se-
quence NM_020193.3 was obtained from the USCS
genome browser [32, 33]. The genome build GRCh37
(hg19) was used. Whole coding regions and exon-intron
boundaries were analysed. EMSY primer sequences and
PCR conditions are available upon request. Sequencing
was performed using the Big Dye Terminator v.3.1 Cycle
Sequencing Kit and the ABIPRISM 3130xl Genetic
Analyser (Applied Biosystems, Foster City, CA, USA). The
sequences were analysed using Sequencher v.5.1 software
(Gene Codes Corporation, Ann Arbor, MI, USA). The
RefSNP number for the identified variants was obtained
from the NCBI Single Nucleotide Polymorphism database
(dbSNP) [34]. Two variants, rs1044265 and rs2513513,
were analysed from controls using TaqMan SNP Genotyp-
ing Assays according to the manufacturer’s instructions
with the ABI Prism® 7900HT instrument and SDS2.2.2
software (Applied Biosystems). The genotyping call rates
of the SNPs were ≥0.98.
Statistical and bioinformatics analyses
Observed variants were tested for Hardy-Weinberg equi-
librium in the controls. The association of variants with
breast/ovarian cancer was examined using Fisher’s exact
test. P values were two-sided, and P < 0.05 was consid-
ered statistically significant. The association of the minor
allele was examined. Odds ratios (OR) and confidence
intervals (CI) were calculated using PLINK v1.07 [35]. If
the variant was not observed in cases or controls, then
the OR was calculated using GraphPad Prism version
5.02 for Windows (GraphPad Software, San Diego, CA,
USA) by adding 0.5 to each value to obtain numeric
values. Linkage disequilibria (LD) between variants, haplo-
type blocks and the association of haplotypes with breast/
ovarian cancer were analysed using Haploview v4.2 [36].
Haplotype blocks were defined using 107 cases and 380
controls via Gabriel’s method, which includes by default
SNPs with minor allele frequencies (MAFs) > 0.05 [37].
The effect of the amino-acid changing variant, c.2861T>G
(Leu954Arg), was predicted using the Pathogenic-or-Not-
Pipeline (PON-P2) programme [38]. The functionality of
the observed SNPs with rs IDs was analysed using
HaploReg v2 [39], including conserved region, open chro-
matin, regulatory chromatin state from the Encyclopaedia
of DNA Elements (ENCODE) [40], protein binding, and al-
tered motifs. The four alternative positions of the deletion
c.2709 + 122delT (chr11 76,253,530–76,253,533) were
analysed for functional elements using RegulomeDB
[41], which includes data for predicted and known
regulatory elements, such as regions of DNA hyper-
sensitivity, binding sites of transcription factors, and
regions with enhancer activity.
The effect of the deletion c.2709 + 122delT on splicing
was analysed using Human Splicing Finder (HSF) v2.4.1
[42]. The alternative deletion locations were analysed
using HSF to detect potential splice sites (HSF matrices),
potential branch points, enhancer motifs (ESE Finder)
and hnRNP motifs (experimental) of SR proteins.
Results
In the present study, we identified 12 different germline
EMSY sequence alterations in index patients from 71
HBOC families, and the alterations were further screened
in a cohort of 36 HBOC patients and healthy controls.
Variant frequencies are presented in Table 1. Two of the
identified alterations were located in the protein-coding
region, five alterations were intronic, and five variants
were located in the 3′UTR. With the exception of one al-
teration, c.2709 + 122delT, all of the identified variants are
reported in the NCBI Single Nucleotide Polymorphism
(SNP) database with rs-numbers (Table 1).
All SNPs were in Hardy Weinberg equilibrium in
controls. The allele frequencies did not significantly differ
between cases and controls (Table 1). One of the SNPs,
rs2508740, was triallelic. Interestingly, the T allele, ob-
served in one control sample, has not previously been re-
ported in the SNP database. However, this control sample
was not included in the association testing of the SNP.
One of the two variants observed in the protein-coding re-
gion rs184345272 resulted in an amino acid substitution
of a hydrophobic leucine with a positively charged argin-
ine at position 954. The heterozygous rs184345272 variant
was identified in two patients (2 of 106, 1.9%) and three
controls (3 of 376, 0.8%) (OR = 2.40; P = 0.3). PON-P2
predicts the unknown effects of substitutions.
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The most interesting finding was the rare novel se-
quence alteration, c.2709 + 122delT (Fig. 1). The precise
location of the deleted T could not be determined based
on the sequence because of a stretch of four T bases in
the reference sequence (chr11 76,253,530–76,253,533).
This deletion has been named according to the Human
Genome Variation Society (HGVS) nomenclature (http://
varnomen.hgvs.org, v.15.11). The heterozygous deletion
was identified in one patient (1 of 107, 0.9%) with bilateral
BC diagnosed at 39 and 42 years of age. However, none of
the controls (0 of 897, 0%) had this deletion (OR = 25.28;
P = 0.1) (Table 1), and it was not observed in a cohort of
404 BC cases unselected for family history (data not
shown). The deletion carrier patient died of BC at age 52.
The clinical features of the patient included invasive
ductal type grade 1 tumour in the left breast and invasive
ductal type grade 2 tumour in the right breast. Both the
tumours had oestrogen and progesterone receptor
positive and human epidermal growth factor receptor
2 negative statuses. The patient’s mother had BC di-
agnosed at age 51, and the father had pancreatic can-
cer diagnosed at age 64. The patient had one healthy
brother. Additionally, the deletion carrier patient had
four other heterozygous EMSY variants, rs42445443,
rs2508740, rs2513513, and rs1044265.
Based on haplotype block analysis, seven observed var-
iants (rs4245443, rs2508740, rs11363199, rs3753051,
rs2513513, rs187735484 and rs1044265) formed a haplo-
type block (Fig. 2). A total of six haplotypes were ob-
served. The haplotype AAATAAA was more common in
controls (2.6%) than cases (0.5%) with a borderline
Table 1 Identified EMSY sequence alterations
Nucleotide
change
Amino acid
change
Position rs number Genotype distribution n (%)a P-value OR; 95% CI
Cases Controls
c.1108 + 40A > G − 76,183,924 rs4245443 16/49/42 (15.0/45.8/39.3) 54/182/137 (14.5/48.8/36.7) 0.8 0.96; 0.70–1.31
c.1514-4G > A − 76,227,182 rs2508740 15/50/42 (14.0/46.7/39.3) 44/178/149 (11.9/48.0/40.1) 0.7 1.07; 0.78–1.46
c.1685-14C > T − 76,234,185 rs11600501 103/4/0 (96.3/3.7/0) 366/11/0 (97.1/2.9/0) 0.8 1.29; 0.41–4.08
c.1995 + 47delA − 76,237,726 rs11363199 49/44/14 (45.8/41.1/13.1) 168/168/41 (44.6/44.6/10.8) 0.9 1.02; 0.74–1.41
c.2709 + 122delT − 76,253,530–
76,253,533
− 106/1/0 (99.1/0.9/0) 897/0/0 (100/0/0) 0.1 25.28; 1.02–625.0
c.2861 T > G p.Leu954Arg 76,255,454 rs184345272 104/2/0 (98.1/1.9/0) 376/3/0 (99.2/0.8/0) 0.3 2.40; 0.40–14.44
c.3648 T > C p.Thr1216Thr 76,257,215 rs3753051 49/44/14 (45.8/41.1/13.1) 166/165/41/ (44.6/44.4/11.0) 0.9 1.02; 0.74–1.41
c.*343A > G − 76,261,533 rs2513513 16/45/46 (15.0/42.1/43.0) 55/186/139 (14.5/48.9/36.6) 0.5 0.88; 0.64–1.21
c.*631C > G − 76,261,821 rs148932730 105/2/0 (98.1/1.9/0) 370/5/0 (98.7/1.3/0) 0.7 1.41; 0.27–7.30
c.*744A > C − 76,261,934 rs187735484 98/9/0 (91.6/8.4/0) 331/45/0 (88.0/12.0/0) 0.4 0.69; 0.33–1.44
c.*753G > C − 76,261,943 rs72932407 99/8/0 (92.5/7.5/0) 351/27/0 (92.9/7.1/0) 0.8 1.05; 0.47–2.34
c.*938A > Gb − 76,262,128 rs1044265 38/51/18 (35.5/47.7/16.8) 351/417/128 (39.2/46.5/14.3) 0.4 1.14; 0.85–1.52
CI confidence interval, OR odds ratio
aGenotype distribution denotes homozygotes/heterozygotes/homozygotes in the order indicated in the nucleotide change column. In the case of deletion,
genotype distribution denotes no deletion/heterozygous deletion/homozygous deletion
bDue to the Hardy-Weinberg disequilibrium in 380 controls, the variant was genotyped in a larger number of controls
*3'UTR variant, i.e. the variant is downstream (3') of the translation termination site (http://varnomen.hgvs.org/bg-material/numbering/)
a
b
Fig. 1 The novel germline sequence alteration c.2709 + 122delT in
EMSY. a Control sample sequence without the deletion. b Heterozygous
deletion in a BC patient sample. The precise position of the deleted T is
uncertain (the region where the T has been deleted is underlined in black
in both a and b)
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significance difference (P = 0.05). The SNP rs2508740
was in high LD (r2 ≥ 0.8) with rs3753051, rs11363199,
rs2513513, and rs4245443 (Fig. 2). In addition, high LD
was observed for SNPs rs4245443 and rs2513513 and
SNPs rs11363199 and rs3753051 (Fig. 2).
The functionality of the identified SNPs with rs IDs (all
but c.2709 + 122delT) was analysed in silico using Hap-
loReg v.2 [39] (Table 2). Some differences were observed
in conserved regions between GERP and SiPhy ap-
proaches, but the conserved regions primarily overlapped
with the SNPs located in exonic and 3′UTR regions. The
3′UTR SNPs were located within open chromatin in
several cell lines and coincided with the chromatin states
of strong enhancers. In addition, two intronic variants
(rs11600501 and rs11363199) were located within chro-
matin states of weak enhancers. Nine of the 11 analysed
variants were predicted to affect regulatory motifs. None
of the variants were located within protein binding sites.
The functionality of the c.2709 + 122delT variant was
examined using the Regulome DB [41], and the four
alternative locations of the deletion coincided with the
same functional elements, including the open chromatin
and transcription factor binding site of GATA6
(Additional file 1: Table S1). In addition, the four-base
location coincides with three regulation motif positions.
The effect of c.2709 + 122delT on splicing regulatory
elements was analysed using Human Splicing Finder
[42] (Additional file 1: Table S2), which indicates both
the introduction and deletion of an acceptor splice site
as a result of the deletion of either one of the alternative
nucleotides. The deletion of the third or fourth nucleo-
tide introduced and abolished a potential branch point.
No enhancer motifs of SR proteins or silencer motifs of
hnRNP were affected by this deletion.
Discussion
Genetic factors predisposing to breast and ovarian cancer
primarily remain unknown in HBOC families negative for
BRCA1 and BRCA2 mutations. Here, we screened the
EMSY gene, encoding the BRCA2-interacting protein, for
germline sequence alterations and analysed the association
of the observed variants with breast/ovarian cancer risk.
We utilized a cohort of index individuals from 71 high-risk
BRCA1/2-negative HBOC families previously screened for
germline alterations in seven known BC genes and copy
number alterations at the genome-wide scale [29, 30].
According to previous analyses, no known predisposing
variants have been identified in a majority (87%) of the
screened high-risk families [29, 30], indicating the existence
of yet unknown gene variants contributing to breast/ovar-
ian cancer susceptibility. To our knowledge, this study is
the first to screen the EMSY gene for germline variations in
relation to breast/ovarian cancer in high-risk families.
We identified 12 different variants in the coding re-
gions and exon-intron boundaries, but none of these
variants showed a statistically significant association with
breast/ovarian cancer risk at the population level, which
may reflect the limited sample size in the present study.
Moreover, haplotype analysis identified one haplotype as
more common in controls compared to cases but with
borderline significance difference. However, the identi-
fied variants, particularly the rare novel deletion,
c.2709 + 122delT, could be important predisposing fac-
tors in individual patients and in a few cancer families.
Interestingly, the deletion carrier patient was affected
with bilateral BC, which may indicate that this deletion
contributes to a poor clinical outcome of the disease.
The deletion carrier patient did not have deleterious mu-
tations or copy number changes in the previously
screened BC genes, BRCA1, BRCA2, CHEK2, PALB2,
BRIP1, RAD50, and CDH1 [29, 30]. Unfortunately, we
did not obtain blood samples from the relatives of the
deletion carrier patient to examine the segregation of
the deletion with the disease. Although this deletion is
located in an intronic region, it may represent a func-
tional variant, according to the results of the in silico
functional analyses. Thus, further studies of this deletion
are warranted. Of note, during the review process of this
manuscript, the deletion was published in the dbSNP
and received reference SNP id number 983125332.
Only one missense variant (rs184345272) was identi-
fied in the protein-coding region of EMSY, suggesting
that mutations are either rare or not tolerated. The
Fig. 2 The haplotype block structure. Haplotype analysis included
the genotypes of the observed variants from 107 breast and/or
ovarian cancer cases and 380 controls. The first alternative marker
position was used for c.2079 + 122delT. Linkage disequilibrium (LD)
values (r2 × 100) are represented in the chart in shades of black. The
figure was obtained using Haploview [36]
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rs184345272 variant, predicted to have unknown effect
on protein function, was 2.4 times more common in
cases compared to controls, but obviously a larger num-
ber of samples should be screened to determine whether
this variant could be a low-risk allele. Interestingly, five
of the 12 (41.6%) alterations occurred in the 3′UTR and
were predicted to play functional roles. Further screen-
ing of these variants would be interesting, particularly
for the rs148932730 variant, which was detected as 1.4
times more common in cases vs. controls.
No truncating mutations, such as frameshift or non-
sense mutations, were detected. Because EMSY is ampli-
fied or over-expressed in breast and ovarian cancer
tumours [13, 20–23, 25, 26], predisposing germline alter-
ations are expected to result in the gain-of-function rather
than the loss-of-function of EMSY. Based on the in silico
functional annotation, either of the alternatives can be
ruled out, since, for example, the potential effect of the
c.2709 + 122delT deletion on splicing might affect the
function of EMSY. Unfortunately, tumour DNA was not
available from the deletion patient for additional analysis,
for example, loss of heterozygosity (LOH). Therefore,
further functional studies are needed to clarify these find-
ings and characterize the effects of the variants on the
functions of other genes through gene regulation.
Common EMSY variations associated with breast and
ovarian cancer risks have previously been examined in
British population-based studies [43]. Three out of the
six SNPs observed in the British study [43] (rs4245443,
rs2508740, and rs11600501) were also identified in the
cohort in the present study. We did not observe an asso-
ciation of these SNPs with breast/ovarian cancer risk,
consistent with previous results [43].
We previously examined the association of EMSY SNPs
with prostate cancer predisposition and identified a rare
intronic SNP that increases the risk of aggressive prostate
cancer (referred to as aggressive SNP) [28]. Interestingly,
the aggressive SNP was segregated with breast cancer in a
prostate cancer family [28]. However, in the present study,
we did not detect the aggressive SNP. Since we only
screened one individual per breast/ovarian cancer family,
we cannot rule out that the other affected family members
in the examined cohort could be carriers of the previously
detected aggressive SNP.
Table 2 Functional annotation of the identified EMSY SNPs with rs IDs
SNP Location Conserved region Open chromatina; Regulatory chromatin statea; Protein
binding
Motifs changed
GERP SiPhy Cell IDb (Cell IDb)
rs4245443 intron No No – – – Pou1f1_2, YY1_known6
rs2508740 intron No Yes – – – –
rs11600501 intron Yes Yes – 7_Weak_Enhancer (HepG2) – EWSR1-FLI1, GATA_known8,
TATA_disc7
rs11363199 intron No No – 7_Weak_Enhancer (HepG2) – Foxa_known4, Pou1f1_2,
Pou2f2_known2, Pou3f2_2, Sox_5
rs184345272 exon Yes Yes – – – NRSF_known3
rs3753051 exon Yes Yes HeLa-S3 – – CEBPB_disc2, Foxa_known2
rs2513513 3′UTR Yes Yes HA-sp., HCPEpiC, 5_Strong_Enhancer (Huvec) – –
HMVEC-dBl-Neo
rs148932730 3′UTR Yes Yes – 4_Strong_Enhancer (Huvec) – DMRT2, Nanog_disc2, Sox_13,
Sox_14, Sox_16, Sox_18, Sox_19,
Sox_2, Sox_4, Sox_9
rs187735484 3′UTR Yes No HMVEC-LBl, 4_Strong_Enhancer (Huvec) – TATA_disc7
HMVEC-dLy-Neo
rs72932407 3′UTR Yes No HBMEC, HMVEC-LBl, 4_Strong_Enhancer (Huvec) – MAZ, SREBP_known3
HMVEC-dLy-Neo,
HPAEC, HRGEC
rs1044265 3′UTR Yes Yes HUVEC 5_Strong_Enhancer (Huvec) – Foxo_3, Mef2_known1, Mef2_known6,
Pou2f2_known2, TCF4_known3
aThe ENCODE data [40]
bHeLa-S3 cervical carcinoma, HA-sp. astrocytes spinal cord, HCPEpiC choroid plexus epithelial cells, HMVEC-dBl-Neo neonatal blood microvascular endothelial cells,
dermal-derived, HMVEC-LBl blood microvascular endothelial cells, lung-derived, HMVEC-dLy-Neo neonatal lymphatic microvascular endothelial cells, dermal-derived,
HBMEC brain microvascular endothelial cells, HPAEC pulmonary artery endothelial cells, HRGEC renal glomerular endothelial cells, HUVEC umbilical vein endothelial
cells, HepG2 hepatocellular carcinoma
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Conclusions
In conclusion, this study is the first to analyse the role of
germline EMSY sequence alterations in HBOC predis-
position in Finnish families. None of the observed EMSY
variants showed statistically significant associations with
breast/ovarian cancer risk at the population level. Based
on the results, we cannot exclude the likelihood variants
contributing to cancer risk in certain high-risk families,
perhaps as private mutations. The variants could be used
to determine cancer risk with other predisposing muta-
tions in these families. Further analyses are warranted,
particularly for the rare novel intronic deletion and 3′
UTR variants predicted to have functional roles.
Additional file
Additional file 1: Table S1. Functional annotation of the location of
the c.2709 + 122delT deletion. Table S2. The effect of the
c.2709 + 122delT variant on splicing regulatory elements. (DOCX 16 kb)
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